|

Atezolizumab 1200 mg abs day 1 q22 (iv) Clinical Trials

1 actively recruiting trial

Also known as: Carboplatin AUC5 day 1 q22 (iv), Nab-Paclitaxel 100 mg/m2 day 1,8,15 q22

Pipeline

Phase 2: 1

Top Sponsors

  • University Hospital Heidelberg1

Indications

  • NSCLC, Stage IIIA1
  • NSCLC Stage II1
  • NSCLC Stage IIIB1
  • Lung Cancer1
  • Cancer1

Other1 trial

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.